HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.

The study, published in JACC: Advances, highlights the potential of the HeartBeam System to aid in the early detection of heart attacks, a critical factor in improving patient outcomes. HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.

The implications of this study are significant for emergency medicine and cardiac care. Rapid identification of heart attack risk in patients with chest pain can expedite treatment and reduce mortality. The ability to use a portable, cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG could revolutionize pre-hospital assessment. The study’s results suggest that with a personal baseline ECG, the algorithm’s accuracy approaches 93%, underscoring the value of longitudinal patient data.

HeartBeam’s technology is designed to enable physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care outside of a medical facility. This redefines the future of cardiac health management by allowing for continuous monitoring and early intervention. The company’s cleared indications for use are detailed on their website at HeartBeam Indications. For more information on the company and its latest news, visit their newsroom at IBN Newsroom.

Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company’s filings with the SEC, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.